Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Announces IND Approval of ASC10 for Monkeypox Indication by U.S. FDA
2022-11-16
Voluntary Announcement - Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022
2022-11-07
Voluntary Announcement - Ascletis’ Strategic Partner Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with ASC40 (Denifanstat), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis
2022-11-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2022-11-03
Voluntary Announcement - Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
2022-11-02
Inside Information - Ascletis Announces Signing License and Supply Agreement of Ritonavir for COVID-19 Drug PAXLOVID™ in Mainland China with Pfizer
2022-10-28
Voluntary Announcement - Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
2022-10-26
Voluntary Announcement - Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
2022-10-10
Voluntary Announcement - Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
2022-10-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
2022-09-30

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1